Week in Review: August 5–9

Flu researchers propose H7N9 studies; NIH makes deal to share HeLa genome; herbal “remedies” can cause cancer; scientists record grid cell activity in humans

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

WIKIPEDIA, CYNTHIA S. GOLDSMITH AND THOMAS ROWEStudying dangerous pathogens is a double-edged sword. Bringing them into the lab and engineering them to become more virulent or more easily transmitted risks the accidental or purposeful release of a potentially deadly agent. On the other hand, without a deeper understanding of the threat, researchers may not be able to properly defend the population against a natural outbreak. These issues came to a head last year when researchers performed so-called “gain-of-function” experiments on the lethal H5N1 bird flu virus. The scientific community is now confronted with a similar dilemma in the face of H7N9, which has infected at least 133 people in China and killed 43 since March.

To preempt the negative fallout of such research on H7N9, a group of 22 prominent influenza researchers this week published a letter about how to approach the virus, emphasizing the need for a strict review process and the use of secure facilities. Signatories on the letter, published in both Nature and Science, include the leaders of last year’s H5N1 projects—Ron Fouchier from the Erasmus Medical Center and Yoshihiro Kawaoka from the University of Wisconsin-Madison.

“One of the main accusations last time around was that the flu community wasn’t being transparent about our work,” Fouchier told The Scientist. “Now, we’re trying to be upfront about what needs to be done, how it could be done, and how we could do it safely.”

WIKIMEDIA, THE LACKS FAMILYAfter the genome of the commonly used cell line HeLa was published in March, science writer Rebecca Skloot and others raised the ethical concern that the family of Henrietta Lacks, from whom the cells were taken without permission in the early 1950s, had not given its consent to the publication. Shortly thereafter, the genome was retracted. Now, in consultation with the surviving family members of Henrietta Lacks, the National Institutes of Health (NIH) has announced a framework for sharing the retracted genome sequence, as well as another HeLa genome sequenced by NIH-funded researchers at the University of Washington in Seattle. The agreement, announced this week in Nature, will allow researchers to apply for access, assuming they plan to use the data solely for biomedical research purposes and formally acknowledge the contribution of Henrietta and her family.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo